Prothena reported $-43009000 in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Agios Pharmaceuticals AGIO:US USD -89109000 6.24M
Akebia Therapeutics AKBA:US USD -38570000 96.43M
ALKERMES ALKS:US USD -41044000 25.98M
Alnylam Pharmaceuticals ALNY:US USD -247440000 65.85M
Amgen AMGN:US USD 3.5B 62M
Biogen BIIB:US USD 992.8M 82.9M
Biomarin Pharmaceutical BMRN:US USD 27.91M 36.51M
Bluebird Bio BLUE:US USD -85093000 14.32M
Exelixis EXEL:US USD 88.28M 206K
Intercept Pharmaceuticals ICPT:US USD -10064000 808K
Intra Cellular Therapies ITCI:US USD -55459000 32.29M
Macrogenics MGNX:US USD -22111000 16.82M
Nektar Therapeutics NKTR:US USD -34794000 9.48M
Neurocrine Biosciences NBIX:US USD 91.8M 33.2M
Regeneron Pharmaceuticals REGN:US USD 1.33B 49.4M
Seattle Genetics SGEN:US USD -175213000 59.32M
Ultragenyx Pharmaceutical RARE:US USD -220372000 83.26M
Vertex Pharmaceuticals VRTX:US USD 1.16B 6.8M
Vital Therapies VTL:US USD -20099000 491K
Xoma XOMA:US USD -4368000 398K
YTE INCY:US USD 134.94M 141.85M